Clinical trial
A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors
NCT05153772 is registered in ClinicalTrials.gov with Orano Med LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors
- Lead sponsor
- Orano Med LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 21, 2021
- Completion date
- December 31, 2030
- Enrollment
- 69 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.